Table 1– Patient demographics and clinical characteristics at screening.

	Placebo	Salmeterol	GSK961081
			Twice daily			Once daily
			100 μg	200 μg	400 μg	100 μg	400 μg	800 μg
ITT subjects n	81	47	52	50	54	50	50	52
Age years	63±7	61±7	62±9	61±9	63±8	63±9	62±8	61±9
Male %	70	62	71	64	70	64	52	67
BMI kg·m−2	26±4	26±4	26±4	26±4	26±4	26±4	27±4	26±4
Current smoker %	44	62	54	66	46	40	54	48
Concurrent ICS use %	59	55	58	60	56	60	54	56
Reversible to salbutamol# %	33	36	33	34	37	32	26	31
FEV1 L¶	1.56±0.53	1.48±0.47	1.55±0.50	1.59±0.46	1.62±0.47	1.63±0.49	1.53±0.45	1.56±0.42
FEV1 % pred¶	49±11	48±10	50±10	51±10	51±10	53±10	52±10	51±10
FEV1 % reversibility	12±11	12±16	12±14	13±13	14±11	11±12	12±12	13±13
FEV1/FVC ratio¶	0.49±0.10	0.50±0.10	0.51±0.09	0.50±0.09	0.50±0.10	0.50±0.10	0.52±0.10	0.51±0.09

Data are presented as mean±sd, unless otherwise stated. ITT: intent-to-treat; BMI: body mass index; ICS: inhaled corticosteroid; FEV₁: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity. ^#: reversibility to salbutamol defined as increase in FEV₁ of 200 mL and 12% following salbutamol administration; ^¶: post-salbutamol measurements.